Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia

[1]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[2]  Xuelin Huang,et al.  Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.

[3]  Christoph Ziegenhain,et al.  The impact of amplification on differential expression analyses by RNA-seq , 2016, Scientific Reports.

[4]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[5]  V. Beneš,et al.  Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation , 2015, Haematologica.

[6]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[7]  S. Rottenberg,et al.  Minimal residual disease in cancer therapy--Small things make all the difference. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[9]  W. Hiddemann,et al.  An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging , 2015, PloS one.

[10]  M. Schrappe.  Detection and management of minimal residual disease in acute lymphoblastic leukemia. , 2014, Hematology. American Society of Hematology. Education Program.

[11]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[12]  S. Dudoit,et al.  Normalization of RNA-seq data using factor analysis of control genes or samples , 2014, Nature Biotechnology.

[13]  W. Bodmer,et al.  Cancer cell lines for drug discovery and development. , 2014, Cancer research.

[14]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[15]  D. Cacchiarelli,et al.  Characterization of directed differentiation by high-throughput single-cell RNA-Seq , 2014, bioRxiv.

[16]  A. Trumpp,et al.  Label retaining cells in cancer--the dormant root of evil? , 2013, Cancer letters.

[17]  Arndt von Haeseler,et al.  NextGenMap: fast and accurate read mapping in highly polymorphic genomes , 2013, Bioinform..

[18]  Åsa K. Björklund,et al.  Smart-seq2 for sensitive full-length transcriptome profiling in single cells , 2013, Nature Methods.

[19]  A. Protopopov,et al.  Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment , 2013, Nature Cell Biology.

[20]  Gilles Celeux,et al.  Data-based filtering for replicated high-throughput transcriptome sequencing experiments , 2013, Bioinform..

[21]  M. Greaves,et al.  Acute lymphoblastic leukaemia , 2013, The Lancet.

[22]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[23]  P. Woll,et al.  Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia , 2013, Leukemia.

[24]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[25]  I. Jeremias,et al.  In Vivo Imaging Enables High Resolution Preclinical Trials on Patients’ Leukemia Cells Growing in Mice , 2012, PloS one.

[26]  M. D. Den Boer,et al.  Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations , 2012, EMBO molecular medicine.

[27]  F. Allgöwer,et al.  Analysis and Simulation of Division- and Label-Structured Population Models , 2012, Bulletin of mathematical biology.

[28]  Y. Pawitan,et al.  Network enrichment analysis: extension of gene-set enrichment analysis to gene networks , 2012, BMC Bioinformatics.

[29]  K. Kreuzer,et al.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.

[30]  I. Jeremias,et al.  Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. , 2012, Blood.

[31]  Martin J Firth,et al.  Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. , 2012, Leukemia research.

[32]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[33]  J. Tchinda,et al.  Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. , 2011, Blood.

[34]  M. Raaijmakers.  Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system , 2011, Haematologica.

[35]  Hans Clevers,et al.  The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.

[36]  Sebastian Bonhoeffer,et al.  Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation , 2011, The Journal of experimental medicine.

[37]  A. Kohlmann,et al.  Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. , 2010, Cancer treatment reviews.

[38]  Andreas Trumpp,et al.  Targeting leukemic stem cells by breaking their dormancy , 2010, Molecular oncology.

[39]  A. Trumpp,et al.  Awakening dormant haematopoietic stem cells , 2010, Nature Reviews Immunology.

[40]  O. Ohara,et al.  Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells , 2010, Science Translational Medicine.

[41]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[42]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[43]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[44]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[45]  M. Raffeld,et al.  Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2 , 2008, Leukemia.

[46]  Rob Pieters,et al.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. , 2008, Cancer cell.

[47]  J. Okamura,et al.  CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL , 2008, Leukemia.

[48]  Sean J. Morrison,et al.  Stem Cells and Niches: Mechanisms That Promote Stem Cell Maintenance throughout Life , 2008, Cell.

[49]  T. Enver,et al.  Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia , 2008, Science.

[50]  T. Holyoake,et al.  Transcriptional Analysis of Quiescent and Proliferating CD34+ Human Hemopoietic Cells from Normal and Chronic Myeloid Leukemia Sources , 2007, Stem cells.

[51]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Anderson,et al.  Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia , 2005, Nature Medicine.

[53]  Jeanne Kowalski,et al.  Microarray and Serial Analysis of Gene Expression Analyses Identify Known and Novel Transcripts Overexpressed in Hematopoietic Stem Cells , 2004, Cancer Research.

[54]  R. Lock,et al.  Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. , 2004, Blood.

[55]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.

[56]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[57]  A. Zander,et al.  Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. , 1997, Human gene therapy.

[58]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[59]  J. Dick,et al.  A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. , 1989, Science.

[60]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[61]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[62]  W. Hiddemann,et al.  Use of polymorphisms in the noncoding region of the human mitochondrial genome to identify potential contamination of human leukemia-lymphoma cell lines. , 2004, The hematology journal : the official journal of the European Haematology Association.

[63]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .